Plain-English translation of NCT06671054 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing a new medication called AP1189 to see if it works better than current treatments for early rheumatoid arthritis. You would take this medication by mouth every day for 12 weeks, combined with methotrexate (a standard arthritis treatment). The researchers want to find the best dose by comparing three different strengths against a placebo (dummy pill).
Rheumatoid arthritis can cause permanent joint damage if not treated quickly and effectively. This trial exists to see whether this medication could offer patients a better treatment option, especially in those newly diagnosed before significant damage occurs.
You likely qualify if…
You likely don't qualify if…
You would visit the clinic regularly over 12 weeks and take a daily oral medication (either the new treatment at one of three doses, or a placebo) along with methotrexate. The study uses a "blind" design, meaning you won't know which dose you're receiving. Researchers will check your joints, measure inflammation in your blood, and monitor how you're responding to treatment throughout the trial.
AI-generated summary from trial data · Jun 11, 2026 · Not medical advice
United States
Bulgaria